Haemopoietic growth factor and dose intensity in high-grade and intermediate-grade lymphoma.
Here we review the evidence that cytotoxic dose intensity is an important determinant of outcome in high- and intermediate-grade non-Hodgkin's lymphoma. The results of retrospective analyses and prospective studies support this proposition but confirmatory studies are required. We discuss the role of haemopoietic growth factors and mobilized peripheral blood progenitor cells to increase dose intensity. Studies using these modalities will enable the importance of dose intensity to be tested.
Pettengell
R
R
CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester, United Kingdom.
Crowther
D
D
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016913:Blood Component Transfusion; D001804:Blood Transfusion, Autologous; D001855:Bone Marrow Diseases / Q000139:chemically induced / Q000628:therapy*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D016298:Hematopoietic Cell Growth Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000401:mortality; D015337:Multicenter Studies as Topic; D015999:Multivariate Analysis; D011379:Prognosis; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012074:Remission Induction; D012189:Retrospective Studies; D016879:Salvage Therapy; D016019:Survival Analysis; D016896:Treatment Outcome
D016298:Hematopoietic Cell Growth Factors; D007155:Immunologic Factors; D011994:Recombinant Proteins